These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. Lee WC; Kang D; Causevic E; Herdt AR; Eckman EA; Eckman CB J Neurosci; 2010 Apr; 30(16):5489-97. PubMed ID: 20410102 [TBL] [Abstract][Full Text] [Related]
3. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. Hossain MA; Otomo T; Saito S; Ohno K; Sakuraba H; Hamada Y; Ozono K; Sakai N Gene; 2014 Jan; 534(2):144-54. PubMed ID: 24252386 [TBL] [Abstract][Full Text] [Related]
4. Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity. Shin D; Feltri ML; Wrabetz L J Neurosci; 2016 Feb; 36(6):1858-70. PubMed ID: 26865610 [TBL] [Abstract][Full Text] [Related]
12. New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones. Spratley SJ; Deane JE J Neurosci Res; 2016 Nov; 94(11):1203-19. PubMed ID: 27638604 [TBL] [Abstract][Full Text] [Related]
13. Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease. Jang DS; Ye W; Guimei T; Solomon M; Southall N; Hu X; Marugan J; Ferrer M; Maegawa GH J Neurosci Res; 2016 Nov; 94(11):1231-45. PubMed ID: 27638606 [TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants. Spratley SJ; Hill CH; Viuff AH; Edgar JR; Skjødt K; Deane JE Traffic; 2016 Aug; 17(8):908-22. PubMed ID: 27126738 [TBL] [Abstract][Full Text] [Related]
15. Chemical chaperone therapy: luciferase assay for screening of β-galactosidase mutations. Li L; Higaki K; Ninomiya H; Luan Z; Iida M; Ogawa S; Suzuki Y; Ohno K; Nanba E Mol Genet Metab; 2010 Dec; 101(4):364-9. PubMed ID: 20826101 [TBL] [Abstract][Full Text] [Related]
16. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Rafi MA; Zhi Rao H; Passini MA; Curtis M; Vanier MT; Zaka M; Luzi P; Wolfe JH; Wenger DA Mol Ther; 2005 May; 11(5):734-44. PubMed ID: 15851012 [TBL] [Abstract][Full Text] [Related]
17. A novel homozygous GALC mutation: very early onset and rapidly progressive Krabbe disease. Kardas F; Uzak AS; Hossain MA; Sakai N; Canpolat M; Yıkılmaz A Gene; 2013 Mar; 517(1):125-7. PubMed ID: 23276707 [TBL] [Abstract][Full Text] [Related]
18. GALC mutations in Chinese patients with late-onset Krabbe disease: a case report. Zhuang S; Kong L; Li C; Chen L; Zhang T BMC Neurol; 2019 Jun; 19(1):122. PubMed ID: 31185936 [TBL] [Abstract][Full Text] [Related]
19. Fibroblast screening for chaperone therapy in beta-galactosidosis. Iwasaki H; Watanabe H; Iida M; Ogawa S; Tabe M; Higaki K; Nanba E; Suzuki Y Brain Dev; 2006 Sep; 28(8):482-6. PubMed ID: 16617000 [TBL] [Abstract][Full Text] [Related]
20. Four novel GALC gene mutations in two Chinese patients with Krabbe disease. Yang Y; Ren X; Xu Q; Wang C; Liu H; He X Gene; 2013 May; 519(2):381-4. PubMed ID: 23462331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]